newsfilter
← Latest News
GlobeNewswire·

PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

  • PolyPid Ltd. will host a virtual Investor Day on October 28, 2026, at 11:30 a.m. ET to outline its "PolyPid 2030" long-term vision & pipeline strategy.
  • Management will provide an update on D-PLEX₁₀₀, the lead product candidate for preventing colorectal surgical site infections, which is under FDA Priority Review with a PDUFA goal date of November 28, 2026.
  • The event will introduce PD01B, a new candidate based on Kynatrix™ delivery technology being developed for treating diabetic foot infections.
  • Warren S. Joseph, DPM, FIDSA, a specialist in lower extremity infectious diseases, will discuss the clinical burden of diabetic foot infections & the potential of locally delivered, controlled-release antibiotic therapy.
  • A live Q&A session featuring Dr. Joseph & PolyPid management will follow the formal presentations.
  • D-PLEX₁₀₀ received Breakthrough Therapy Designation from the FDA & demonstrated a 60% relative risk reduction in SSI incidence during the Phase 3 SHIELD II trial.
  • The Kynatrix™ technology enables prolonged release of doxycycline at the surgical site for 30 days to prevent infections caused by antibiotic-resistant bacteria.
  • The webcast & dial-in details are available at the provided links, with a replay to be posted on the company's investor website following the event.